Brentuximab vedotin (Adcetris@), approved by FDA in 2011, composes of MMAE and cAC10 mAb (chimeric IgG1 antibody) via a protease-cleavable dipeptide linker to target tumor antigen CD30 (also known as TNFRSF8) for the treatment of Hodgkin’s lymphoma and ALCL (ki-1 lymphoma) (Senter and Sievers, 2012; Younes et al., 2012). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.